THE CAMBRIDGE DECLARATION: Towards Clinical Trials for Drug-Resistant Tuberculosis Cambridge, Massachusetts, USA June 12, 2008
Added by Cat Oettinger on 19 Jun 2008
Download: Cambridge_Declaration_July_4_2008.pdf (159.7 KB)
Summary: THE CAMBRIDGE DECLARATION:
Towards Clinical Trials for Drug-Resistant Tuberculosis
Cambridge, Massachusetts, USA
June 12, 2008
Because
• today millions of people are living with drug-resistant tuberculosis (TB),
• drug-resistant TB, which is transmissible and deadly, represents a public-health emergency,
• universal access to effective TB treatment is unachievable with current tools,
• inadequate treatment of drug-resistant TB leads to the emergence of extensively drug-resistant (XDR) TB, and
• there are huge gaps in our understanding of how to best treat drug-resistant TB,
we express extreme concern that the best available treatments are of limited efficacy and are reaching only a small fraction of people who need them. The others are left to die, with no or inadequate treatment.
On June 10-12, 2008, stakeholders from communities, NGOs, governments, donors, industry, and academia met in Cambridge, Massachusetts, USA, and declared the formation of a movement that will:
• conduct priority clinical trials that test strategies in adults and children:
> to shorten and improve treatment for drug-resistant TB, and
> to prevent drug-resistant TB
• mobilize the resources needed for these trials
• build the capacity of trial sites
• report to stakeholders on progress made, and
• ensure that these efforts complement those of other groups, and address the critical unmet needs outlined above.
For more information, or to join protocol-writing groups, please contact:
drtbworkshop @gmail.com
SIGNATORIES, 2 July 2008
1. Ms. Paula Akugizibwe, AIDS and Rights Alliance for Southern Africa, Namibia
2. Dr. Elijah Amooti, African Eye Trust, England
3. Mr. Sidney Atwood, Brigham and Women’s Hospital, USA
4. Dr. Renuka Babu, Medicine in Need, USA
5. Dr. Jaime Bayona, Socios En Salud-Sucursal Peru, Peru
6. Dr. Mercedes Becerra, Harvard Medical School, USA
7. Dr. Nulda Beyers, Desmond Tutu TB Centre, South Africa
8. Dr. Cesar Bonilla, National Health Strategy for TB Prevention and Control, Peru
9. Dr. Maryline Bonnet, Epicentre / Médecins Sans Frontières, Switzerland
10. Dr. William Burman, Denver Public Health, USA
11. Dr. Jose A. Caminero, International Union against Tuberculosis and Lung Disease, France
12. Dr. Peter Cegielski, U.S. Centers for Disease Control and Prevention, USA
13. Dr. Richard Chaisson, Johns Hopkins University School of Medicine, USA
14. Dr. Frank Cobelens, KNCV Tuberculosis Foundation, The Netherlands
15. Dr. Theodore Cohen, Brigham and Women’s Hospital, USA
16. Dr. Margareth Dalcolmo, Helio Fraga Reference Center - FIOCRUZ / MoH, Brazil
17. Dr. Charles Daley, National Jewish Medical and Research Center, USA
18. Dr. Manfred Danilovits, Tartu University Lung Clinic, National Tuberculosis Program, Estonia
19. Mr. Karel De Beule, Tibotec, Belgium
20. Dr. Victor De Gruttola, Harvard School of Public Health, USA
21. Dr. Mary Ann DeGroote, Colorado State University, USA
22. Dr. Tine De Marez, Tibotec, Inc., USA
23. Dr. Ashwin Dharmadhikari, Brigham & Women’s Hospital, USA
24. Ms. Nancy Dianis, Westat, USA
25. Dr. Anne Donnelly, Project Inform, USA
26. Dr. Kelly Dooley, Johns Hopkins University School of Medicine, USA
27. Dr. Kathleen Eisenach, University of Arkansas for Medical Sciences, USA
28. Dr. Gerald Friedland, Yale University School of Medicine, USA
29. Dr. Robert Gerety, Medicine in Need, USA
30. Dr. Ann Ginsberg, Global Alliance for TB Drug Development, USA
31. Dr. Howard Grossman, Fenway Community Health, USA
32. Dr. Abdul Hamid Salim, Damien Foundation, Bangladesh
33. Mr. Mark Harrington, Treatment Action Group, USA
34. Dr. Martin Hirsch, Harvard Medical School, USA
35. Dr. Timothy Holtz, U.S. Centers for Disease Control and Prevention, USA
36. Dr. Robert Horsburgh, Boston University School of Public Health, USA
37. Dr. Gary Horwith, Sequella, Inc., USA
38. Dr. Frauke Jochims, Médecins Sans Frontières, Switzerland
39. Dr. Salmaan Keshavjee, Harvard Medical School, USA
40. Dr. Michael Kimerling, University of Alabama at Birmingham School of Medicine, USA
41. Dr. Serena Koenig, Brigham and Women’s Hospital, USA
42. Dr. Kitty Lambregts, KNCV Tuberculosis Foundation, The Netherlands, and MDR-TB Working Group of the Stop TB Partnership, Switzerland
43. Dr. Vaira Leimane, State Centre of Tuberculosis and Lung Diseases, Latvia
44. Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Disease, France
45. Dr. Pushpa Malla, National Tuberculosis Centre, National Tuberculosis Program, Nepal
46. Dr. William Mac Kenzie, U.S. Centers for Disease Control and Prevention, USA
47. Dr. Helen McIlleron, University of Cape Town, South Africa
48. Dr. Charles Mgone, European and Developing Countries Clinical Trials Partnership, Netherlands
49. Dr. Fuad Mirzayev, World Health Organization, Switzerland
50. Prof. Denis Mitchison, St. George’s Hospital, UK
51. Dr. Carole Mitnick, Harvard Medical School, USA
52. Dr. Edward Nardell, Brigham and Women’s Hospital, USA
53. Dr. Eric Nuermberger, Johns Hopkins University School of Medicine, USA
54. Mrs. Carol Nyirenda, Treatment Advocacy and Literacy Campaign, Zambia
55. Dr. Thomas Nyirenda, European and Developing Countries Clinical Trials Partnership, South Africa
56. Ms. Lesley Odendal, Treatment Action Campaign, South Africa
57. Dr. Charles Peloquin, National Jewish Medical and Research Center, USA
58. Dr. Sergey Popov, Moscow Medical Academy, Russia
59. Dr. Alexander Pym, Medical Research Council of South Africa, South Africa.
60. Dr. Lee Reichman, University of Medicine and Dentistry of New Jersey, USA
61. Dr. Hind Satti, Partners In Health, Lesotho
62. Dr. Rajeswari Ramachandran, Tuberculosis Research Centre, India
63. Dr. Francisco Rosas, Vivir. Participación, Incidencia, y Transparencia, A.C., Mexico
64. Dr. Leonard Sacks, U.S. Food and Drug Administration, USA
65. Dr. Jussi Saukkonen, Boston University School of Medicine, USA
66. Dr. Neil Schluger, Columbia University Medical Center, USA
67. Dr. Kwonjune Seung, Brigham and Women’s Hospital, USA
68. Dr. Alexander Sloutsky, Massachusetts State Laboratory Institute, USA
69. Dr. Thelma Tupasi, Tropical Disease Foundation, Philippines
70. Dr. Frank van Leth, KNCV Tuberculosis Foundation, The Netherlands
71. Mr. Wim Vandevelde, European AIDS Treatment Group, Belgium
72. Dr. Francis Varaine, Médecins Sans Frontières, France
73. Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention, USA
74. Dr. Tido von Schoen-Angerer, Médecins Sans Frontières, Switzerland
75. Dr. Diana Weil, World Health Organization, Switzerland
76. Dr. Charles Wells, Otsuka America Pharmaceutical, Inc., USA
77. Dr. Matteo Zignol, World Health Organization, Switzerland
The workshop was convened by partners of the MDR-TB Working Group of the Stop-TB Partnership. It was sponsored and organized by: Boston University School of Public Health, International Union Against TB & Lung Disease, KNCV Tuberculosis Foundation, MDR-TB Working Group of the Stop-TB Partnership, Médecins Sans Frontières, Partners In Health/Harvard Medical School, Potts Memorial Foundation, Treatment Action Group, World Health Organization.
Keywords: RESIST-TB, Workshop Materials
Source: Participants of the DR TB Clinical Trials Workshop
Publication Date: July 4, 2008
Language: English